IDMIT is a department of the Jacob Institute of the Alternative Energies and Atomic Energy Commission (CEA), jointly operated with Inserm and the Université Paris-Saclay. The CEA is also the coordinator of the national infrastructure for preclinical research hosted by the IDMIT department. CEA is a key player in research, development and innovation in the areas of low carbon energies, and technological research for Industry and Health. IDMIT infrastructure is one the largest facility in Europe dedicated to preclinical research in infectious disease with extended core facilities for BSL2 and BSL3 programs, comprehensive in vivo imaging technologies (from microscopy to whole body PET-CT) and state-of-the-art laboratories for cellular and molecular microbiology and immunology. IDMIT develops preclinical research programs on human vaccines and antimicrobial treatments and is organized to provide scientific community with access to the expertise and capabilities.
The role of IDMIT in Flavivaccine project is to evaluate the immune responses and protection induced by the consortium vaccine candidates and to elucidate its mechanisms of action.
Contact: anne-sophie.beignon@cea.fr